CTS Eventim AG & Co. KGaA (0EEE), the Munich-based ticketing and live entertainment group, has disclosed a significant share acquisition by a member of its supervisory body. Dr Cornelius Baur, a member of the company's administrative or supervisory board, purchased shares in the company on 13 November 2026 at an aggregated value of €373,417.35. The transaction was executed on the Xetra trading platform and disclosed publicly on 17 November 2026 in accordance with regulatory requirements. Insider buying of this scale can attract investor attention as it may reflect board-level confidence in the company's underlying business.
Key Points
- CTS Eventim AG & Co. KGaA (0EEE), Munich-headquartered ticketing and live entertainment operator
- Dr Cornelius Baur, a supervisory board member, acquired company shares on 13 November 2026 via Xetra
- Total aggregated transaction value: €373,417.35 at a weighted average price of approximately €61.58 per share
- Investors may watch for further director dealings or any forthcoming corporate updates from CTS Eventim
Dr Cornelius Baur's Share Purchase Executed Across Multiple Price Levels on Xetra
The regulatory disclosure confirms that Dr Baur's acquisition was executed across five separate price tranches on 13 November 2026. Purchases were made at prices ranging from €61.40 to €61.60 per share, with the largest single tranche — valued at €285,700.80 — transacted at €61.60 per share. Smaller tranches were completed at €61.40, €61.45, €61.50, and €61.55 per share. The aggregated weighted average price across all tranches was €61.5793783, with a total aggregated volume of €373,417.35. All trades were conducted on the Xetra exchange, identified by the market identifier code XETR.
CTS Eventim's Business Profile and the Context of This Regulatory Notification
CTS Eventim AG & Co. KGaA is headquartered at Rablstrasse 26, Munich, Germany, and operates under the LEI code 529900FDHSN08UBJII80. The company is a major European provider of ticketing services and live entertainment, with its shares carrying the ISIN DE0005470306. This notification represents an initial disclosure under regulations governing transactions by persons discharging managerial responsibilities, commonly known as PDMR reporting. Such filings are mandatory under European market abuse rules when qualifying individuals transact in an issuer's securities.
Significance of Supervisory Board Insider Buying for CTS Eventim Investors
Transactions reported by persons in managerial or supervisory roles are closely monitored by market participants because they can signal board-level perspectives on a company's valuation or prospects. Dr Baur's purchase, totalling over €373,000, represents a material personal commitment to CTS Eventim shares at current market prices. However, the announcement does not provide any accompanying commentary, stated rationale, or forward-looking guidance from Dr Baur or the company. Investors should therefore treat this disclosure as a factual regulatory filing rather than an indicator of any specific forthcoming corporate development, and conduct their own assessment accordingly.




Please wait processing your request...